MedTrace Logo

DSUVIA in Patients With SCD VOC Present in the ED

NCT05388188 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-05-24

No results posted yet for this study

Summary

This is an observational study to improve the treatment of patients with Sickle Cell Disease Vaso-Occlusive Crisis by administering pain medications more quickly after the patient arrives in the emergency department. Specifically, we are using a sublingual opioid called sufentanil \[Dsuvia\] that has already been approved by the Food and Drug Administration (FDA) for the treatment of acute pain. It is being studied as part of this research study to find out if we can relieve the patients pain more quickly and decrease the amount of time the patient needs to spend in the hospital by avoiding a hospital admission after the patients emergency department encounter if the patients pain is adequately controlled.

Conditions

  • Sickle-Cell Disease With Crisis

Interventions

DRUG

sublingual sufentanil

Dsuvia in patients with SCD VOC as a bridging medication.

Sponsors & Collaborators

  • Jason Wilson

    lead OTHER

Principal Investigators

  • Jason Wilson, MD · Tampa General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2023-04-30
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388188 on ClinicalTrials.gov